NorthWest Biotherapeutics Inc (NWBO)

[Extremist223]

I wonder with (1) and (14) do they still cover the claims of 38-46? And when does a t-cell stop being a t-cell?

edit: remember that claims 35-47 had to be removed and a species of checkpoint inhibitor selected.

1. A method of treating cancer or initiating, enhancing, or prolonging an antitumor response in a subject in need thereof comprising administering to the subject a therapeutic agent in combination with an agent that is a checkpoint inhibitor.

14 . The method of claim 1, wherein treatment is determined by a clinical outcome; an increase, enhancement or prolongation of anti-tumor activity by T cells; an increase in the number of anti-tumor T cells or activated T cells as compared with the number prior to treatment or a combination thereof.


As you will see the following claims are related to adoptive t-cell therapy, what Iovance is working on.


38. A combination therapy for the treatment of cancer wherein the combination therapy comprises adoptive T cell therapy and a checkpoint inhibitor.
39. The combination therapy of claim 38, wherein the adoptive T cell therapy comprises autologous T-cells.
40. The combination therapy of claim 39, wherein the autologous T-cells are targeted against tumor antigens.
41. The combination therapy of claim 38, wherein the adoptive T cell therapy comprises allogenic T-cells.
42. The combination therapy of claim 41, wherein the autologous T-cells are targeted against tumor antigens.
43. The combination therapy of claim 38, wherein the checkpoint inhibitor is a PD-1 or a PDL-1 checkpoint inhibitor.
44. A method of enhancing an anti-tumor or anti-cancer immune response, the method comprising administering to a subject adoptive T cell therapy and a checkpoint inhibitor.
45. The method of claim 44, wherein the adoptive T cell therapy is administered before the checkpoint inhibitor.
46. The method of claim 45, wherein the adoptive T cell therapy is administered 1-30 days before the checkpoint inhibitor.